It’s a divorce everyone has an opinion on.
In the ongoing escalation of the feud between Harvard University and the Trump White House has imperiled hundreds of research grants at Harvard’s medical school.
Dana-Farber’s bold split from the Brigham is a culmination of Boston oncology’s complicated history
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Harvard University has sued the Trump administration a second time since the start of the ongoing feud between the university and White House.
Harvard University filed an amended lawsuit against the Trump administration, seeking to add two more federal agencies as defendants and to address the administration’s widening efforts to cut the university’s federal funding—now targeting over $2.6 billion and all future grants.
Federal judges in Maryland, New Hampshire and Washington, DC, blocked the Trump administration from following through on threats to cut off funding to universities that engage in DEI efforts.
Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies.
Kimberly Stegmaier was named chair of Pediatric Oncology at Dana-Farber Cancer Institute and associate chief of the Division of Hematology/Oncology at Boston Children’s Hospital. Her appointment is effective April 1.
